GHK-Cu influences gene expression, upregulating genes associated with tissue repair while downregulating inflammatory markers
UK Regulatory Position on GLP-1 Medicines and Cancer The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) maintain active surveillance of GLP-1 receptor agonists and have issued clear guidance regarding their safety profile, including cancer-related considerations
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) explicitly lists "agents when used for weight loss" among the categories of drugs Medicare Part D cannot cover
In individuals with obesity, GLP-1 secretion from intestinal L-cells may itself be impaired meaning the body is already deficient in the very hormone these medications replace
It is 50 to 100 times more potent than morphine
This also helps people get better control of their blood sugar, or glycemic control